Challenge
9 million Americans struggle with the debilitating symptoms of COPD with Chronic Bronchitis.
The RejuvenAir System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA) and received unconditional IDE (Investigational Device Exemption) approval to initiate a pivotal clinical study to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB).
The challenge is to communicate this optimism to potential clinical study participants.